Grifols, S.A.
General ticker "GIFOF" information:
- Sector: Health Care
- Industry: Drug Manufacturers - General
- Capitalization: $5.7B (TTM average)
Grifols, S.A. follows the US Stock Market performance with the rate: 28.1%.
Estimated limits based on current volatility of 0.0%: low 8.81$, high 8.81$
Factors to consider:
- Company pays dividends (semi-annually): last record date 2025-08-12, amount 0.18$ (Y4.09%)
- Total employees count: 157 as of 2010
- Earnings for 9 months up through Q3 exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2024-12-31 to 2026-12-31
- 2024-12-31 to 2025-12-31 estimated range: [9.65$, 15.73$]
- 2025-12-31 to 2026-12-31 estimated range: [10.65$, 17.08$]
Financial Metrics affecting the GIFOF estimates:
- Positive: with PPE of 33.7 at the end of fiscal year the price was very low
- Positive: 7.86 < Operating profit margin, % of 16.53
- Positive: Operating cash flow per share per price, % of 16.53 > 13.24
- Positive: 18.93 < Shareholder equity ratio, % of 27.49 <= 41.86
- Positive: Industry operating profit margin (median), % of 20.85 > 9.92
- Positive: -2.95 < Return on assets ratio (scaled to [-100,100]) of 0.73
- Positive: Investing cash flow per share per price, % of 16.25 > -0.66
Short-term GIFOF quotes
Long-term GIFOF plot with estimates
Financial data
| YTD | 2022-12-31 | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Operating Revenue | €6,063.97MM | €6,591.98MM | €7,212.38MM |
| Operating Expenses | €5,281.53MM | €5,792.58MM | €6,020.37MM |
| Operating Income | €782.44MM | €799.40MM | €1,192.02MM |
| Non-Operating Income | €-444.42MM | €-575.38MM | €-748.02MM |
| Interest Expense | €444.54MM | €516.06MM | €739.94MM |
| R&D Expense | €361.14MM | €395.28MM | €384.04MM |
| Income(Loss) | €338.01MM | €224.02MM | €444.00MM |
| Taxes | €90.11MM | €43.35MM | €231.19MM |
| Profit(Loss)* | €208.28MM | €59.31MM | €156.92MM |
| Stockholders Equity | €6,129.94MM | €5,827.17MM | €5,883.73MM |
| Inventory | €3,201.36MM | €3,459.28MM | €3,560.10MM |
| Assets | €21,533.98MM | €21,441.05MM | €21,405.24MM |
| Operating Cash Flow | €-10.87MM | €208.28MM | €902.17MM |
| Capital expenditure | €375.56MM | €295.42MM | €371.37MM |
| Investing Cash Flow | €-1,978.82MM | €-397.64MM | €886.67MM |
| Financing Cash Flow | €-173.49MM | €186.04MM | €-1,358.71MM |
| Earnings Per Share** | €0.31 | €0.09 | €0.22 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.